tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Lexicon submits additional data to FDA for benefit-risk profile of Zynquista
PremiumThe FlyLexicon submits additional data to FDA for benefit-risk profile of Zynquista
20d ago
Lexicon Pharmaceuticals’ Sotagliflozin Shows Promising Cardiovascular Benefits, Earning Buy Rating
Premium
Ratings
Lexicon Pharmaceuticals’ Sotagliflozin Shows Promising Cardiovascular Benefits, Earning Buy Rating
25d ago
Lexicon announces post-hoc analysis of clinical data presented at ESC
Premium
The Fly
Lexicon announces post-hoc analysis of clinical data presented at ESC
26d ago
Lexicon Pharmaceuticals Reports Strong Q2 2025 Earnings
PremiumCompany AnnouncementsLexicon Pharmaceuticals Reports Strong Q2 2025 Earnings
2M ago
Lexicon Pharmaceuticals: Strategic R&D Advancements and Strong Financial Performance Justify Buy Rating
Premium
Ratings
Lexicon Pharmaceuticals: Strategic R&D Advancements and Strong Financial Performance Justify Buy Rating
2M ago
Lexicon reports Q2 EPS 1c, consensus (8c)
Premium
The Fly
Lexicon reports Q2 EPS 1c, consensus (8c)
2M ago
Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension
PremiumCompany AnnouncementsLexicon Pharmaceuticals Granted Nasdaq Compliance Extension
3M ago
Promising Outlook for Lexicon Pharmaceuticals’ Sotagliflozin in Type 1 Diabetes Management
Premium
Ratings
Promising Outlook for Lexicon Pharmaceuticals’ Sotagliflozin in Type 1 Diabetes Management
3M ago
Lexicon announces post-hoc analysis of clinical data on sotagliflozin
Premium
The Fly
Lexicon announces post-hoc analysis of clinical data on sotagliflozin
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100